NBY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NBY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
NovaBay Pharmaceuticals's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.03.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 40.80% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 35.20% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 42.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of NovaBay Pharmaceuticals was 63.30% per year. The lowest was -33.10% per year. And the median was 31.70% per year.
For the Biotechnology subindustry, NovaBay Pharmaceuticals's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, NovaBay Pharmaceuticals's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where NovaBay Pharmaceuticals's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
NovaBay Pharmaceuticals (AMEX:NBY) 3-Year FCF Growth Rate Explanation
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Thank you for viewing the detailed overview of NovaBay Pharmaceuticals's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Tommy Law | officer: Interim CFO | 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608 |
Jeffrey Kunin | officer: President, DERMAdoctor, LLC | 4346 BELGIUM BLVD NW, RIVERSIDE MO 64150 |
Audrey Kunin | officer: Chief Product Officer | 4346 BELGIUM BLVD NW, RIVERSIDE MO 64150 |
Justin Hall | officer: General Counsel | 5980 HORTON STREET, SUITE 550, EMERYVILLE CA 94608 |
Yongxiang Zheng | director | NO.10, UNIT 1, LIJING VILLA, TIANZHU, SHUNYI DISTRICT, BEIJING F4 101316 |
Julie Garlikov | director | 2420 17TH STREET, SUITE 220, DENVER CO 80202 |
Andrew D. Jones | officer: CFO and Treasurer | 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608 |
Mijia Wu | director | SUITE 6C, BLDG 3, YOU YOU CENTURY PLAZA, NO 428 YANG GAO SOUTH ROAD, SHANGHAI F4 CHINA |
Jian Ping Fu | 10 percent owner | LEVEL 1, BLDG 1, GREENWOOD BUSINESS PARK, 301 BURWOOD HWY, BURWOOD C3 3125 |
Wang Xu | officer: NEO - Sr Mgr and Controller | 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608 |
Swan Sit | director | 95 JACKSON STREET, NEWTON MA 02459 |
Yenyou Zheng | director | 1055 WEST HASTINGS STREET, SUITE 1980, VANCOUVER A1 V6E 2E9 |
Xiaopei Wang | director | 2/44 FRANKLIN ROAD, DONCASTER EAST C3 3109 |
Jason Philip Raleigh | officer: Interim CFO and Treasurer | 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608 |
Pioneer Pharma (hong Kong) Co Ltd | 10 percent owner | FLAT 2605, 26/F TRENDY CENTRE, 682 CASTLE PEAK ROAD, KOWLOON K3 000000 |
From GuruFocus
By Marketwired Marketwired • 08-09-2019
By PRNewswire PRNewswire • 05-14-2020
By gurufocus • 08-28-2009
By Marketwired Marketwired • 08-09-2019
By PRNewswire • 09-13-2023
By PRNewswire PRNewswire • 07-13-2020
By PRNewswire PRNewswire • 04-20-2020
By PRNewswire PRNewswire • 10-02-2020
By PRNewswire PRNewswire • 05-15-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.